Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL996985 | 1.00 | ADRB2 (0.37) | ADRB2PDE2A | |
| SCHEMBL1000434 | 1.00 | ADRB2 (0.37) | ADRB2PDE2A | |
| Hydrochloric Acid SCHEMBL17823539 | 0.97 | ADRB2 (0.36) | ADRB2 | |
| Hydrochloric Acid SCHEMBL17824158 | 0.97 | ADRB2 (0.36) | ADRB2 | |
| Hydrochloric Acid SCHEMBL28474912 | 0.97 | ADRB2 (0.36) | ADRB2 | |
| Hydrochloric Acid SCHEMBL28480125 | 0.97 | ADRB2 (0.36) | ADRB2 | |
| SCHEMBL4317136 | 0.79 | ADRB2 (0.37) | ADRB2PDE2A | |
| SCHEMBL3265716 | 0.78 | LMNA (0.32) | — | |
| SCHEMBL24635077 | 0.77 | ADRB2 (0.46) | ADRB2 | |
| SCHEMBL21649988 | 0.77 | ADRB2 (0.46) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | claimed |
| EP-2262766-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2010-12-22 | — | — | EP | claimed |
| WO-2009110985-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| US-20230357218-A1 | N-FORMAMIDOPYRAZOLINE DERIVATIVE AS P2X3 RECEPTOR ANTAGONIST AND USE THEREOF | HANGZHOU WESTAN PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357218-A1 | N-FORMAMIDOPYRAZOLINE DERIVATIVE AS P2X3 RECEPTOR ANTAGONIST AND USE THEREOF | HANGZHOU WESTAN PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4223751-A1 | BENZAMIDE COMPOUND AND USE THEREOF | Humanwell Healthcare (Group) Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| EP-4223751-A1 | BENZAMIDE COMPOUND AND USE THEREOF | Humanwell Healthcare (Group) Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20230227445-A1 | BENZAMIDE COMPOUND AND USE THEREOF | HUMANWELL HEALTHCARE (GROUP) CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227445-A1 | BENZAMIDE COMPOUND AND USE THEREOF | HUMANWELL HEALTHCARE (GROUP) CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| EP-2136639-A1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009110985-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2008-11-06 | — | — | US | disclosed |
| WO-2008130481-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130481-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008123963-A1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008123963-A1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227445-A1 | BENZAMIDE COMPOUND AND USE THEREOF | P2RX3, P2RX4, P2RX7 | ADRB2 214/4885PDE2A 891/4885 |
| US-20230357218-A1 | N-FORMAMIDOPYRAZOLINE DERIVATIVE AS P2X3 RECEPTOR ANTAGONIST AND USE THEREOF | P2RX3, P2RX4, P2RX7 | ADRB2 221/4885PDE2A 1146/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | ADRB2 3213/4885PDE2A 1427/4885 |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | CNR2, CNR1, CBR1 | ADRB2 347/4885PDE2A 888/4885 |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | IL1B, ADORA2B, AVPR1B | ADRB2 225/4885PDE2A 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.